Recombinant Human EPO | Z101439

abm | Recombinant Human EPO | Z101439

EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of Epo comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of Epo is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behavior of Epo in vivo. Non-glycosylated Epo has an extremely short biological half life. It still binds to its receptor and may even have a higher specific activity in vitro.

Functions:

Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be 3.8 x 10^5 IU/mg.

Organism:

Human

Source:

CHO

Alias:

INN=Epoetin
Recombinant Human Erythropoietin-Alpha (EPO)

Gene Symbol:

EPO

Gene ID:

2056

Accession:

P01588

Formulation:

Lyophilized from a 0.2 μm filtered solution in PBS (pH 7)

Solubility:

A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

Appearance:

Lyophilized Powder

Molecular Weight (kDa):

20

Molecular Weight 2 (kDA):

N/A

Molecular Weight 3 (kDA):

N/A

Purity:

>95% as determined by SDS-PAGE

Concentration:

<1.0 EU/μg of recombinant protein as determined by the LAL method.

Shipping Condition :

Ambient Temperature

Storage Condition:

The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.